Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 2, 1998, Pages 651-660

  Helton, David R ^a,b   Tizzano, Joseph P ^a   Monn, James A ^a   Schoepp, Darryle D ^a   Kallman, Mary Jeanne ^a  

^a ELI LILLY AND COMPANY   (United States)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; CENTRAL DEPRESSANT AGENT; DIAZEPAM; EGLUMETAD; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; METABOTROPIC RECEPTOR; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MODEL; FEAR; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOUSE; NEUROMUSCULAR DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STARTLE REFLEX;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BICYCLO COMPOUNDS; CONVULSANTS; CYCLIC AMP; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEXOBARBITAL; HUMANS; MALE; MICE; MOTOR ACTIVITY; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SLEEP; STARTLE REACTION;

EID: 0031933951     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Anthony EW and Nevins ME (1993) Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 250:317-324.
2. Campeau S and Davis M (1995) Involvement of the central nucleus and basolateral complex of the amygdala in fear conditioning measured with fear-potentiated startle in rats trained concurrently with auditory and visual conditioned stimuli. J Neurosci 15:2301-2311.
3. Coyle JT (1987) Excitotoxins, in Psychopharmacology: The Third Generation of Progress (Meltzer HY ed.) pp 333-340, Raven Press, NY.
4. Dantzer, R (1977) Behavioral effects of benzodiazepines: A review. Biobehavioral Rev 1:71-86.
5. Danysz W, Parsons CG, Bresink I and Quack G (1995) Glutamate in CNS disorders. Drug News and Perspectives 8:261-277.
6. Davis M (1979) Diazepam and flurazepam: Effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology 62:1-7.
7. Davis M (1986) Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav Neurosci 100:814-824.
8. Davis M (1992) The role of the amygdala in fear-potentiated startle: Implications for animal models of anxiety. Trends Pharmacol Sci 13:35-41.
9. Davis M, Falls WA, Campeau S and Kim M (1993) Fear-potentiated startle: A neural and pharmacological analysis. Behav Brain Res 58:175-198.
10. Davis M, Rainnie D and Cassell M (1994) Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci 17:208-214.
11. Dawson GR and Tricklebank MD (1995) Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 16:33-36.
12. Greenblatt D and Shader R (1978) Dependence, tolerance, and addiction to benzodiazepines: Clinical and pharmacokinetic considerations. Drug Metab Rev 8:13-28.
13. Helton DR, Berger J, Czachura JF, Rasmussen K and Kallman MJ (1995) Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol Biochem Behav 53:493-502.
14. Hollmann M and Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
15. Kehne JH, Cassella JV and Davis M (1988) Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology 94:8-13.
16. Kim M, Campeau S, Falls WA and Davis M (1993) Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks expression of fear-potentiated startle. Behav Neural Biol 59:5-8.
17. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185.
18. Miserendino MJD, Sananes CB, Melia KR and Davis M (1990) Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 345:716-718.
19. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR and Schoepp DD (1997) Design, synthesis and pharmacological characterization of +)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: A potent, selective, systemically active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537.
20. Nakanishi S and Masu M (1994) Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct 23:319-348.
21. Nicoletti F, Meek JL, Iadarola MJ, Chuang DM, Roth BL and Costa E (1986) Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. J Neurochem 46:40-46.
22. Ohishi H, Shigemoto R, Nakanishi S and Mizuno N (1993a) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:1009-1018.
23. Ohishi H, Shigemoto R, Nakanishi S and Mizuno N (1993b) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Compar Neurol 335:252-266.
24. Olsen RW (1982) Drug interactions at the GABA receptor-ionphore complex. Annu Rev Pharmacol Toxicol 22:245-277.
25. Petralia RS, Wang Y-X, Niedzielski AS and Wenthold RJ (1996) The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71:949-976.
26. Pin J-P and Duvoisin R (1995) The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 34:1-26.
27. Rainnie DG, Asprodini EK and Shinnick-Gallagher P (1991) Excitatory transmission in the basolateral amygdala. J Neurophysiol 66:986-998.
28. Rainnie DG and Shinnick-Gallagher P (1992) Trans-ACPD and L-APB presynaptically inhibit excitatory glutamatergic transmission in the basolateral amygdala (BLA). Neurosci Lett 139:87-91.
29. Riblet LA, Taylor DP, Eison MS and Stanton HC (1982) Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 43:11-16.
30. Schoepp DD and Johnson BG (1988) Excitatory amino acid agonist-antagonist interactions at 2-amino-4-phosphonobutyric acid-sensitive quisqualate receptors coupled to phosphoinositide hydrolysis in slices of rat hippocampus. J Neurochem 50:1605-1613.
31. Schoepp DD and Conn PJ (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14:13-20.
32. Schoepp DD (1994) Novel functions for subtypes of metabotropic glutamate receptors. Neurochem Int 24:439-449.
33. Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerham SL, Burnett JP, Belagaje R, Bleakman D and Monn JA (1997) LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology 36:1-11.
34. Sladeczek F, Pin J-P, Recasens M, Bockaert J and Weiss S (1985) Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 317:717-719.
35. Sugiyama H, Ito I and Hirono C (1987) A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature 325:531-533.
36. Swinyard EA, Brown WC and Goodman LS (1952) Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106:319-330.
37. 1a agonists, in 5-HT1a Agonists, 5-HT-3 Antagonists and Benzodiazepines: Their Comparative Behavioral Pharmacology (Rodgers RJ and Cooper SJ eds), pp 107-131, Wiley, Chichester.
38. Wiley JL, Cristello AF and Balster RL (1995) Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur J Pharmacol 294:101-107.
39. Woods JH, Katz JL and Winger G (1987) Abuse liability of benzodiazepines. Pharmacol Rev 39:251-414.
40. Woods JH, Katz JL and Winger G (1992) Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44:151-347.